Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment

Cancer Microenvironment

Volumn 7, Issue 3, 2014, Pages 153-160

  Noman, Muhammad Zaeem ^a   Messai, Yosra ^a   Muret, Jane ^a   Hasmim, Meriem ^a   Chouaib, Salem ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CSC; CTC; Hypoxia; Immune system

Indexed keywords

DEATH RECEPTOR; GRANZYME; HYPOXIA INDUCIBLE FACTOR; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL HYPOXIA; CELL INTERACTION; CELL STRESS; CIRCULATING TUMOR CELL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EPITHELIAL MESENCHYMAL TRANSITION; EVOLUTIONARY ADAPTATION; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; INNATE IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84922099729     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-014-0157-3     Document Type: Article

References (50)

1. Akalay I, Janji B et al (2013) EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. Autophagy 9(7):1104–1106
2. Apostolou P, Toloudi M et al (2012) Cancer stem cells stemness transcription factors expression correlates with breast cancer disease stage. Curr Stem Cell Res Ther 7(6):415–419
3. Azuma T, Yao S et al (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643
4. Baccelli I, Schneeweiss A et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544
5. Blank C, Gajewski TF et al (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54(4):307–314
6. Brizel DM, Scully SP et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56(5):941–943
7. Derre L, Corvaisier M et al (2006) Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 177(5):3100–3107
8. Dewhirst MW, Cao Y et al (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8(6):425–437
9. Driemel, C., H. Kremling, et al. (2013). “Context-dependent adaption of EpCAM expression in early systemic esophageal cancer” Oncogene.
10. Eliane JP, Repollet M et al (2008) Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res 68(14):5529–5532
11. Green TL, Cruse JM et al (2013) Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol 95(2):174–179
12. Green TL, Santos MF et al (2014) Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol 97(1):44–48
13. Gruber I, Landenberger N et al (2013) Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res 33(5):2233–2238
14. Hamai A, Benlalam H et al (2010) Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75(1):1–8
15. Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47
16. Hasmim M, Noman MZ et al (2013) Cutting edge: Hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-beta1. J Immunol 191(12):5802–5806
17. Hoffmann AC, Warnecke-Eberz U et al (2007) Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 95(1):51–54
18. Kallergi G, Markomanolaki H et al (2009) Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 11(6):R84
19. Kallergi G, Papadaki MA et al (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13(3):R59
20. Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129(3):465–472
21. Konishi J, Yamazaki K et al (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10(15):5094–5100
22. Kudo-Saito C, Shirako H et al (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15(3):195–206
23. Lau KW, Tian YM et al (2007) Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer 96(8):1284–1292
24. Li Z, Bao S et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501–513
25. Liu S, Li N et al (2013) "Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.". Gastroenterology 144(5):1031–1041
26. Makino Y, Uenishi R et al (2007) Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. J Biol Chem 282(19):14073–14082
27. Malmberg KJ, Levitsky V et al (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110(10):1515–1523
28. Marincola FM, Jaffee EM et al (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273
29. Medema JP, de Jong J et al (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98(20):11515–11520
30. Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6(6):449–458
31. Noman MZ, Messai Y et al (2011) Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 31(5):357–377
32. Pardal R, Clarke MF et al (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902
33. Raimondi C, Gradilone A et al (2011) Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130(2):449–455
34. Reya T, Morrison SJ et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111
35. Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272(36):22642–22647
36. Schulze K, Gasch C et al (2013) Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133(9):2165–2171
37. Semenza GL (2009) HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 15(33):3839–3843
38. Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91(4):411–429
39. Steinert G, Scholch S et al (2014) Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 74(6):1694–1704
40. Theodoropoulos PA, Polioudaki H et al (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288(1):99–106
41. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454
42. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142
43. Tinhofer I, Saki M et al (2014) Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol 1–6
44. Vander Griend DJ, Karthaus WL et al (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23):9703–9711
45. Vegran F, Boidot R (2013) Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and −6 in cancer cells. Oncoimmunology 2(11):e26328
46. Wang GL, Jiang BH et al (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92(12):5510–5514
47. Wang Y, Liu Y et al (2011) Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8(4):399–411
48. Wohlfart S, Sebinger D et al (2004) FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol 164(3):1081–1089
49. Yie SM, Luo B et al (2006) Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis 23(5–6):279–289
50. Yu M, Bardia A et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584